Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.

Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dièye S, Dieye TN, Esmail H, Goliath R, Huygen K, January V, Ndiaye I, Oni T, Raine M, Romano M, Satti I, Sutton S, Thiam A, Wilkinson KA, Mboup S, Wilkinson RJ, McShane H; MVA85A 030 trial investigators..

Lancet Respir Med. 2015 Mar;3(3):190-200. doi: 10.1016/S2213-2600(15)00037-5. Epub 2015 Feb 26.

2.

Diagnosis of childhood tuberculosis and host RNA expression in Africa.

Anderson ST, Kaforou M, Brent AJ, Wright VJ, Banwell CM, Chagaluka G, Crampin AC, Dockrell HM, French N, Hamilton MS, Hibberd ML, Kern F, Langford PR, Ling L, Mlotha R, Ottenhoff TH, Pienaar S, Pillay V, Scott JA, Twahir H, Wilkinson RJ, Coin LJ, Heyderman RS, Levin M, Eley B; ILULU Consortium.; KIDS TB Study Group..

N Engl J Med. 2014 May 1;370(18):1712-23. doi: 10.1056/NEJMoa1303657.

3.

Evaluation of a semi-automated reporter phage assay for susceptibility testing of Mycobacterium tuberculosis isolates in South Africa.

Banaiee N, January V, Barthus C, Lambrick M, Roditi D, Behr MA, Jacobs WR Jr, Steyn LM.

Tuberculosis (Edinb). 2008 Jan;88(1):64-8. Epub 2007 Nov 5.

Supplemental Content

Loading ...
Support Center